CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03364153
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:54.676141+00:00
Published At: 2026-03-12T00:00:00+00:00
Record Updated At: 2026-04-15
Results Posted At: 2026-03-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stargardt\u0027s Macular Dystrophy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-15"
protocolSection.identificationModule.nctId: "NCT03364153"
protocolSection.identificationModule.officialTitle: "A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura\u2122 (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-03-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.